Hepatocellular Carcinoma (HCC): Recent Updates and Evolving Treatment Paradigms - Episode 12

Tremelimumab Plus Durvalumab in Patients With Advanced HCC: The HIMALAYA Study

Dr R. Katie Kelley shares her thoughts on the four-year updated survival and efficacy data from the phase 3 HIMALAYA trial in patients with advanced hepatocellular carcinoma.

EP. 1: Overview of Hepatocellular Carcinoma (HCC)
EP. 2: Diagnosing Patients With Hepatocellular Carcinoma
EP. 3: Factoring Stage and Hepatic Function Into Treatment Decision-Making for HCC
EP. 4: Treatment Approaches for Patients With Early-Stage HCC
EP. 5: The Role of Adjuvant Therapy in Patients With Early-Stage HCC
EP. 6: Updates in First-Line Systemic Therapy for Advanced HCC: The IMbrave150 Trial
EP. 7: Updates in First-Line Systemic Therapy for Advanced HCC: The HIMALAYA Study
EP. 8: Optimal Sequencing in Patients With Advanced HCC
EP. 9: Safety Profiles of Available Therapies in Advanced HCC
EP. 10: The Future of HCC Treatment
EP. 11: First-Line Systemic Treatment Options for Patients With Advanced HCC
Now Viewing
EP. 12: Tremelimumab Plus Durvalumab in Patients With Advanced HCC: The HIMALAYA Study
EP. 13: Key Safety Outcomes From Updated Analysis of HIMALAYA Trial in Advanced HCC
EP. 14: The CELESTIAL Study: Cabozantinib Monotherapy in Advanced HCC Treatment
EP. 15: Safety and Efficacy Data From the Retrospective Analysis of the CELESTIAL Study in Advanced HCC
EP. 16: Future of Advanced HCC Treatment

Related Content:

Hepatocellular Carcinoma (HCC): Recent Updates and Evolving Treatment Paradigms
Future of Advanced HCC Treatment
Safety and Efficacy Data From the Retrospective Analysis of the CELESTIAL Study in Advanced HCC
The CELESTIAL Study: Cabozantinib Monotherapy in Advanced HCC Treatment